Compare · BIIB vs OKYO
BIIB vs OKYO
Side-by-side comparison of Biogen Inc. (BIIB) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $32.62B, about 398.4x OKYO ($81.9M).
- BIIB has been more active in the news (9 items in the past 4 weeks vs 8 for OKYO).
- BIIB has more recent analyst coverage (25 ratings vs 2 for OKYO).
- Company
- Biogen Inc.
- OKYO Pharma Limited
- Price
- -
- -
- Market cap
- $32.62B
- $81.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 2
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest BIIB
- LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
- LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Biogen upgraded by Wolfe Research with a new price target
- SEC Form 3 filed by new insider Parini Michael
- Biogen Completes Acquisition of RayThera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Biogen Inc.
Latest OKYO
- Amendment: SEC Form 20-F/A filed by OKYO Pharma Limited
- Amendment: CHIEF DEVELOPMENT OFFICER Jacob Gary S bought $4,900 worth of shares (3,500 units at $1.40), increasing direct ownership by 3% to 112,420 units (SEC Form 4)
- Amendment: CHIEF EXECUTIVE OFFICER Dempsey Robert John bought $23,085 worth of shares (15,000 units at $1.54) (SEC Form 4)
- Amendment: Director Brancaccio John P bought $7,385 worth of shares (5,000 units at $1.48), increasing direct ownership by 17% to 35,201 units (SEC Form 4)
- Amendment: Chief Scientific Officer Patil Rajkumar V. bought $5,011 worth of shares (3,363 units at $1.49), increasing direct ownership by 20% to 20,030 units (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $35,000 worth of shares (25,000 units at $1.40) (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $32,625 worth of shares (22,500 units at $1.45) (SEC Form 4)
- Amendment: CHIEF MEDICAL OFFICER Mantelli Flavio bought $28,000 worth of shares (20,000 units at $1.40) (SEC Form 4)
- Chief Scientific Officer Patil Rajkumar V. was granted 3,363 shares, increasing direct ownership by 20% to 20,030 units (SEC Form 4)
- New insider Patil Rajkumar V. claimed ownership of 16,667 shares (SEC Form 3)